Evandro Bezerra, MD
Hematology · Columbus, OHNPI 1245657592
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,055 of the $16,219 with a category attached, or 92.8%. 4 manufacturers reported payments, led by AstraZeneca at 49.0% of the total. 2025 is the largest year on record at $7,954, 2.7 times the $2,924 reported in 2023.
Across 17 payments — averaging $954.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Gilead$5K
- Novartis$3K
- Vertex$71
Across 13 payments — averaging $13,978 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$101K
- AstraZeneca$44K
- Swedish Orphan Biovitrum AB$36K
What the payments were for
- Consulting fees$15,05593%
- Travel & lodging$6894%
- Food & beverage$4753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $7,954 |
| Gilead | 8 | $5,463 |
| Novartis | 2 | $2,731 |
| Vertex | 2 | $71 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,219 in reported general payments places this provider in the 60th percentile of 84 hematology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 12 | $194,891 |
| Acyclovir | 16 | $132 |
| Magnesium Sulfate | 12 | $55 |
Paid to pharmacies, not to this prescriber.
Other hematology in Columbus
- Uma BorateColumbus$323K
- Sam PenzaColumbus$256K
- Spero CatalandColumbus$245K
- Kami MaddocksColumbus$236K
- Narendranath EpperlaColumbus$199K
- Yvonne EfeberaColumbus$169K
- Naresh BummaColumbus$109K
- Kerry RogersColumbus$100K
- Jennifer WoyachColumbus$73K
- Hannah ChoeColumbus$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.